Company Appendix News Today

Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholde...

Weebit Nano Ltd (ASX: WBT, Weebit or Company) is pleased to provide this activity report for the quarter ended 30 June 2023 (Q4 FY23), along with the Company’s Appendix 4C cash flow report.

Successfully listed on NASDAQ; expanding operations in the USA; executing on strategy...

MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68Ga) gozetotide). U.S. Launch Update: Full reimbursement in the U.S. to be effective from July 1...

Anatara Lifesciences Limited (ASX:ANR) Monthly Activities Report    Monthly Activities ReportMelbourne, July 28, 2021 AEST (ABN Newswire) - Anatara Lifesciences Limited ( ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 30 June 2021 (Q4 FY21), along with the Companys Appendix 4C cash flow report. Commenting on the quarter, CEO Steve Lydeamore said, "Anatara is pleased ...

Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anataras human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.Read Full Article▸ On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the share...

Anatara Lifesciences Ltd (ASX:ANR) Q3 FY21 Activities Report    Q3 FY21 Activities ReportMelbourne, April 27, 2021 AEST (ABN Newswire) - Anatara Lifesciences ( ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Companys Appendix 4C cash flow report. Commenting on the quarter, CEO Steve Lydeamore said, "Anatara is pleased to have success...